Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences Ltd (TLSA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $144M; returns 1 day -5.0%, 1 week -9.5%, 1 year -50.0%.

Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology company focused on developing transformative therapies for neurodegenerative and inflammatory diseases. Their primary focus is on intranasal foralumab, a fully human anti-CD3 monoclonal antibody, currently in clinical development for diseases like Multiple Sclerosis, Alzheimer's, and ALS.

Groups TLSA belongs to

• Biotechnology
• Life Sciences
• Clinical Stage Biotech
• United Kingdom Companies
• Monoclonal Antibodies
• Neuroscience
• Healthcare
• Neurological Disorders
• Alzheimer's Disease
• Autoimmune Diseases
• Clinical Stage

TLSA financial model: income statement, cash flow and balance sheet